As Losses Narrow, Is Zai Lab Finally Finding its Winning Formula?

The biotech breaks a cycle of widening losses as it shifts towards developing new drugs Key Takeaways: Zai Lab reported its loss shrank 65% in the first quarter of the year while its revenues continued to rise The company slashed its R&D costs by cutting licensing payments for existing drugs while spending more on finding new remedies By Tina Yip Zai Lab, like many pharma start-ups in China, kickstarted its business by licensing proven drugs from other companies. Investors had high hopes that it would later transform into an innovator…

Read More »

Amid Slowing Sales at Home, Innovent Biologics Stumbles Overseas

Cancer drug maker ended a tie-up to bring one of its drugs to North America last week, less than two months after its best-selling product was rejected by the FDA Key takeaways: Innovent Biologics terminated a plan to sell its bevacizumab biosimilar in North America with a local partner after trials for the drug fell behind schedule The company’s loss tripled last year on growing competition for its core product, whose sales fell 22% in this year’s first-quarter By Molly Wen With domestic competition heating up in the crowded China…

Read More »

Junshi Biosciences Back in the Red, Pins Hopes on Covid Drugs

The innovative drug developer reported a first-quarter loss as a result of a steep drop in licensing revenue Key Takeaways: Junshi Biosciences’ revenue tumbled 61% in the first quarter, reflecting its high dependence on income from overseas licensing The company is hoping for steadier future revenue from an oral Covid-19 drug now in Phase 3 multi-regional clinical trials (MRCTs) By Molly Wen 2021 was a bittersweet year for Shanghai Junshi Biosciences Co. Ltd. (1877.HK; 688180.SH). Its Covid-19 neutralizing antibody drug JS016 was a hit overseas and became a major new…

Read More »

InnoCare Pharma Goes Back to Funding Trough With STAR Market Listing

The Hong Kong-traded company will become the latest from the cash-challenged pharma sector to make a second listing on the A-share market Key Takeaways: InnoCare Pharma’s A-share IPO will make it the fourth innovative pharma company with shares traded in Hong Kong and on the mainland’s STAR Market   The company is flush with cash and continues to raise money at every opportunity to finance its R&D By Molly Wen China’s Nasdaq-style STAR Market has become fertile ground for fundraising by innovative yet profit-challenged pharmaceutical companies since its launch in…

Read More »

Cancer Drug Maker BeiGene Takes Action to Mitigate Delisting Risk

Company has changed auditors in a bid to comply with U.S. law and avoid a potential forced delisting from the Nasdaq Key Takeaways: BeiGene has switched auditors for its New York listing to a U.S. company from a Chinese one in a move to comply with U.S. law The change could reduce the company’s threat of being forcibly delisted from the Nasdaq By Doug Young It may have listings in Hong Kong and Shanghai, but cancer drug maker BeiGene Ltd. (BGNE.US; 6160.HK; 668235.SH) is making it clear it wants to…

Read More »

FAST NEWS: SEC Names Five Chinese Stocks at Threat of Delisting

The latest: The U.S. Securities and Exchange Commission (SEC) announced Thursday that it has placed five Chinese companies on a list of companies that could face the threat of delisting under the Foreign Company Accountability Act, including BeiGene, Ltd. (BGNE.US; 6160.HK; 688235.SH), Zai Lab Ltd. (ZLAB.US; 9688.HK), Yum China Holdings Inc. (YUMC.US; 9987.HK HK), Hutchmed (China) Ltd. (HCM.US; 0013.HK) and ACM Research Inc. (ACMR:US). Looking up: There are currently more than 270 Chinese stocks listed in the U.S. The SEC has named only five this time, giving the others time…

Read More »

Hutchmed Roils Markets With Changing of Its Guard, U.S. Delisting Threat

U.S. securities regulator singles out company for potential delisting, a week after Hutchmed announced its CEO will step down after almost 22 years Key Takeaways U.S. securities regulator says Hutchmed is one of five Chinese companies in danger of delisting, a week after company announced the retirement of its longtime CEO Company’s shares have tumbled more than 40% on the developments, even as it reported strong revenue gains for 2021 and nears its first approval to sell a drug in the U.S. By Richard Barbarossa Talk about getting hit when…

Read More »

Zai Lab Revenue Triples, as It Struggles to Break Cycle of Mounting Losses

The biotech company is bringing in bigger sums from its growing stable of drugs approved for sale in China, but is also accelerating its R&D spending Key takeaways: Zai Lab reported its revenue grew 194% last year, but its loss also increased by 162% as it spent heavily on R&D and marketing The company hopes heavy R&D spending can reduce its dependence on licensed products by improving its capacity to innovate By Ken Lo A big revenue jump should be good news for a young biotech company like Zai Lab…

Read More »

New Energy Lands as Hottest Category Among Chinese Concept Stocks in 2021 – Bamboo Works Special Report

Investors kept a close look at China’s solar and wind power stocks last year, but were least interested in the hobbled education sector By Bamboo Works team Chinese concept stocks experienced unprecedented challenges in the Year of the Ox. The small and mid-sized companies covered by Bamboo Works were no exception, also coming under intense pressure. Looking past their stock prices and financial reports, how did these companies perform in terms of media and investor attention? Which companies stood out despite all the pressures? Our special report highlights such trends…

Read More »

FAST NEWS: BeiGene Shares Plunge on STAR Market Trading Debut

The latest: Biotech company BeiGene Ltd. (BGNE.US; 6160.HK; 688235.SH) on Wednesday announced the completion of its 22.2 billion yuan ($3.5 billion) listing on Shanghai’s STAR Market, becoming the world’s first stock to be simultaneously listed in the U.S., Hong Kong and on one of China’s A-share markets. But the stock performed poorly on its debut on concerns about potential new U.S. sanctions against the company. Looking up: The new listing gives BeiGene new funding to invest in drug research, clinical development and on construction of R&D centers and manufacturing sites.…

Read More »